As new medications receive approval, youll have more options to consider
To help avoid gastrointestinal side effects of GLP-1 drugs: Eat slowly and stop when full
tirzepatide adds GIP (dual agonist) and retatrutide adds glucagon (triple agonist), with generally larger weight effects in trials but different tolerability profiles
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing in late 2026, MHRA approval in late 2027 to mid-2028, and NHS access through NICE from 2029 at the earliest
We need to accept people are going to do this whether its safe or not